UOC
IPXL

UBS O'Connor’s Impax Laboratories, Inc. IPXL Stock Holding History

UBS O'Connor’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-176,801
Closed -$8.12M – 816
2015
Q2 		$8.12M Buy
+176,801
New +$8.39M 0.14% 179
2013
Q3 		– Sell
-137,000
Closed -$2.73M – 619
2013
Q2 		$2.73M Buy
+137,000
New +$2.43M 0.05% 298

Other funds holding IPXL

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS O'Connor's IPXL Position: Q3 2015 in Review

UBS O'Connor sold out of Impax Laboratories, Inc. (IPXL) in Q3 2015, closing a stake of 176,801 shares — an estimated $8.12M sold.

UBS O'Connor first reported a position in IPXL in Q2 2013 and held it in 2 quarters. The position peaked at $8.12M in Q2 2015. 195 funds tracked by Wall St. Rank hold IPXL as of Q3 2015.

  • UBS O'Connor reported no remaining Impax Laboratories, Inc. position as of Q3 2015 after selling out during the quarter.
  • UBS O'Connor sold 176,801 Impax Laboratories, Inc. shares in Q3 2015, an estimated $8.12M.
  • UBS O'Connor first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 2 quarters.
  • UBS O'Connor's Impax Laboratories, Inc. position peaked at $8.12M in Q2 2015.
  • 195 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2015.

Based on UBS O'Connor's 13F filing for Q3 2015, filed 13 Nov 2015.